share_log

While Shareholders of Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

While Shareholders of Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

杭州中泰低温科技(SZSE:300435)的股东在过去三年里亏损,但实际盈利却在增长
Simply Wall St ·  10/24 20:48

Hangzhou Zhongtai Cryogenic Technology Corporation (SZSE:300435) shareholders should be happy to see the share price up 24% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In fact, the share price is down 26% in the last three years, falling well short of the market return.

中泰股份(SZSE:300435)的股东应该很高兴,看到股价在上个月上涨了24%。但这并不能掩盖过去三年收益低于理想的事实。事实上,在过去三年中,股价下跌了26%,远远低于市场回报。

On a more encouraging note the company has added CN¥519m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.

更值得鼓舞的是,公司在过去7天内将51900万人民币增加到了其市值中,让我们看看是什么导致了股东在过去三年的亏损。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本杰明·格雷厄姆的话来说:“短期市场是一台投票机,但长期市场是一台称重机”。检查市场情绪如何随时间推移变化的一种方式是查看公司股价和每股收益(EPS)之间的相互作用。

Although the share price is down over three years, Hangzhou Zhongtai Cryogenic Technology actually managed to grow EPS by 5.8% per year in that time. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.

尽管股价在过去三年中下跌,但中泰股份实际上在此期间成功实现了每年5.8%的每股收益增长。这是一个相当棘手的问题,表明可能有一些暂时支撑股价的因素。或者该公司过去受到过度炒作,因此其增长令人失望。

Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

由于EPS的变化似乎与股价的变化不相关,因此值得查看其他指标。

The modest 1.2% dividend yield is unlikely to be guiding the market view of the stock. Revenue is actually up 4.6% over the three years, so the share price drop doesn't seem to hinge on revenue, either. This analysis is just perfunctory, but it might be worth researching Hangzhou Zhongtai Cryogenic Technology more closely, as sometimes stocks fall unfairly. This could present an opportunity.

1.2%的股息率不太可能影响股票的市场观点。实际上,营业收入在过去三年中增长了4.6%,因此股价下跌似乎并不取决于营业收入。这种分析只是敷衍了事,但值得更仔细地研究一下中泰股份,因为有时股票会不公平地下跌。这可能带来一些机会。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

以下图像显示了公司的营业收入和盈利(随时间变化)(单击以查看准确的数字)。

big
SZSE:300435 Earnings and Revenue Growth October 25th 2024
中小企业板300435在2024年10月25日的盈利和营业收入增长情况

If you are thinking of buying or selling Hangzhou Zhongtai Cryogenic Technology stock, you should check out this FREE detailed report on its balance sheet.

如果您考虑买入或卖出中泰股份的股票,您应该查看这份关于其资产负债表的免费详细报告。

A Different Perspective

另一种看法

While the broader market gained around 8.8% in the last year, Hangzhou Zhongtai Cryogenic Technology shareholders lost 7.7% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.9% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Hangzhou Zhongtai Cryogenic Technology better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Hangzhou Zhongtai Cryogenic Technology , and understanding them should be part of your investment process.

尽管去年整体市场上涨了约8.8%,中泰股份的股东却损失了7.7%(甚至包括分红在内)。但是请记住,即使是最好的股票有时也会在一年的时间内表现不佳。遗憾的是,去年的表现可能表明存在未解决的挑战,因为它比过去半个十年的年化损失0.9%还要糟。我们意识到罗斯柴尔德男爵曾说过投资者应该“在街上有血时买入”,但我们警告投资者首先要确定他们正在购买的是一个高质量的业务。长期跟踪股价表现总是很有趣。但要更好地理解中泰股份,我们需要考虑许多其他因素。例如,始终存在的投资风险。我们已经发现了1个关于中泰股份的警告标志,了解它们应该成为您投资过程的一部分。

But note: Hangzhou Zhongtai Cryogenic Technology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

请注意:中泰股份可能不是最好的买入股票。因此,请查看这份免费的有过盈利增长(以及未来增长预测)的有趣公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文中引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发